Extracellular Matrix Proteins and Tumor Angiogenesis

Overview

Journal J Oncol

Specialty Oncology

Date 2010 Jul 31

PMID 20671917

Citations 37

Authors

N E Campbell

L Kellenberger

J Greenaway

R A Moorehead

N M Linnerth-Petrik

J Petrik

Affiliations

Soon will be listed here.

Abstract

Tumor development is a complex process that relies on interaction and communication between a number of cellular compartments. Much of the mass of a solid tumor is comprised of the stroma which is richly invested with extracellular matrix. Within this matrix are a host of matricellular proteins that regulate the expression and function of a myriad of proteins that regulate tumorigenic processes. One of the processes that is vital to tumor growth and progression is angiogenesis, or the formation of new blood vessels from preexisting vasculature. Within the extracellular matrix are structural proteins, a host of proteases, and resident pro- and antiangiogenic factors that control tumor angiogenesis in a tightly regulated fashion. This paper discusses the role that the extracellular matrix and ECM proteins play in the regulation of tumor angiogenesis.

Citing Articles

Decellularized tissues as platforms for digestive system cancer models.

Seifi Z, Khazaei M, Cheraghali D, Rezakhani L Heliyon. 2024; 10(11):e31589.

PMID: 38845895 PMC: 11153114. DOI: 10.1016/j.heliyon.2024.e31589.

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited.

Dzobo K, Senthebane D, Dandara C Cancers (Basel). 2023; 15(2).

PMID: 36672326 PMC: 9856874. DOI: 10.3390/cancers15020376.

Escape from breast tumor dormancy: The convergence of obesity and menopause.

Roy R, Yang J, Shimura T, Merritt L, Alluin J, Man E Proc Natl Acad Sci U S A. 2022; 119(41):e2204758119.

PMID: 36191215 PMC: 9564105. DOI: 10.1073/pnas.2204758119.

Fibrous stroma: Driver and passenger in cancer development.

Sharma V, Letson J, Furuta S Sci Signal. 2022; 15(724):eabg3449.

PMID: 35258999 PMC: 8988932. DOI: 10.1126/scisignal.abg3449.

3D tumor angiogenesis models: recent advances and challenges.

Bhat S, Badiger V, Vasishta S, Chakraborty J, Prasad S, Ghosh S J Cancer Res Clin Oncol. 2021; 147(12):3477-3494.

PMID: 34613483 PMC: 8557138. DOI: 10.1007/s00432-021-03814-0.

References

Chetty C, Lakka S, Bhoopathi P, Kunigal S, Geiss R, Rao J . Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res. 2008; 68(12):4736-45. PMC: 2586602. DOI: 10.1158/0008-5472.CAN-07-6612. View

Hsu S, Volpert O, Steck P, Mikkelsen T, Polverini P, Rao S . Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 1996; 56(24):5684-91. View

Yap R, Veliceasa D, Emmenegger U, Kerbel R, McKay L, Henkin J . Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res. 2005; 11(18):6678-85. DOI: 10.1158/1078-0432.CCR-05-0621. View

Herndon M, Stipp C, Lander A . Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology. 1999; 9(2):143-55. DOI: 10.1093/glycob/9.2.143. View

Goth M, Hubina E, Raptis S, Nagy G, Toth B . Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech. 2002; 60(1):98-106. DOI: 10.1002/jemt.10248. View

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

Dickson P, Hamner J, Sims T, Fraga C, Ng C, Rajasekeran S . Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007; 13(13):3942-50. DOI: 10.1158/1078-0432.CCR-07-0278. View

Baenziger N, Brodie G, MAJERUS P . Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem. 1972; 247(9):2723-31. View

Baenziger N, Brodie G, MAJERUS P . A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci U S A. 1971; 68(1):240-3. PMC: 391203. DOI: 10.1073/pnas.68.1.240. View

10.

Radisky D, Hagios C, Bissell M . Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol. 2001; 11(2):87-95. DOI: 10.1006/scbi.2000.0360. View

11.

Killion J, Radinsky R, Fidler I . Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1999; 17(3):279-84. DOI: 10.1023/a:1006140513233. View

12.

Vazquez F, Hastings G, Ortega M, Lane T, Oikemus S, Lombardo M . METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem. 1999; 274(33):23349-57. DOI: 10.1074/jbc.274.33.23349. View

13.

Pepper M . Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001; 86(1):346-55. View

14.

Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S . Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998; 58(5):1048-51. View

15.

ALVAREZ A, Axelrod J, Whitaker R, Isner P, Bentley R, Dodge R . Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol. 2001; 82(2):273-8. DOI: 10.1006/gyno.2001.6287. View

16.

Marcinkiewicz C, Weinreb P, Calvete J, Kisiel D, Mousa S, Tuszynski G . Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res. 2003; 63(9):2020-3. View

17.

Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff A . Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2006; 26(28):4158-70. DOI: 10.1038/sj.onc.1210182. View

18.

Spurbeck W, Ng C, Strom T, Vanin E, Davidoff A . Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood. 2002; 100(9):3361-8. DOI: 10.1182/blood.V100.9.3361. View

19.

Fernandez C, Butterfield C, Jackson G, Moses M . Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003; 278(42):40989-95. DOI: 10.1074/jbc.M306176200. View

20.

Chlenski A, Guerrero L, Yang Q, Tian Y, Peddinti R, Salwen H . SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene. 2007; 26(31):4513-22. DOI: 10.1038/sj.onc.1210247. View